Das Medizinportal     Aktuelles für medizinische Fachkreise
Menü

Das Medizinportal     Aktuelles für medizinische Fachkreise

Literatur:

Zielgerichtete Therapie des Schilddrüsenkarzinoms

C. Fottner, Mainz (S. 11)

 

  1. Pacini F, Castagna MG, Brilli L, Pentheroudakis G; ESMO Guidelines Working Group.Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012 Oct;23 Suppl 7:vii110-9
  2. Elisei R, Schlumberger MJ, Müller SP, Schöffski P, Brose MS, Shah MH, Licitra L, Jarzab B, Medvedev V, Kreissl MC, Niederle B, Cohen EE, Wirth LJ, Ali H, Hessel C, Yaron Y, Ball D, Nelkin B, Sherman SI. Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol. 2013 Oct 10;31(29):3639-46. 
  3. Schlumberger M. et al.  Final overall survival analysis of EXAM, an international, double-blind, randomized, placebo-controlled phase III trial of cabozantinib (Cabo) in medullary thyroid carcinoma (MTC) patients with documented RECIST progression at baseline. J Clin Oncol 33, 2015 (suppl; abstr 6012)
  4. Brose MS, Nutting CM, Jarzab B, Elisei R, Siena S, Bastholt L, de la Fouchardiere C, Pacini F, Paschke R, Shong YK, Sherman SI, Smit JW, Chung J, Kappeler C, Peña C, Molnár I, Schlumberger MJ; DECISION investigators. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet. 2014 Jul 26;384(9940):319-28. 
  5. Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, Habra MA, Newbold K, Shah MH, Hoff AO, Gianoukakis AG, Kiyota N, Taylor MH, Kim SB, Krzyzanowska MK, Dutcus CE, de las Heras B, Zhu J, Sherman SI. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med. 2015 Feb 12;372(7):621-30. 
  6. Brose MS. Et al. Effect of age and lenvatinib treatment on overall survival for patients with 131I-refractory differentiated thyroid cancer in SELECT. J Clin Oncol 33, 2015 (suppl; abstr 6048)
  7. Newbold K. et al. Efficacy and safety of lenvatinib for the treatment of patients with 131I-refractory differentiated thyroid cancer with and without prior VEGF-targeted therapy. J Clin Oncol 33, 2015 (suppl; abstr 6013)
  8. Tahara M. et al. Pharmacodynamic biomarkers of outcomes in the phase III study of lenvatinib in 131I-refractory differentiated thyroid cancer (SELECT). J Clin Oncol 33, 2015 (suppl; abstr 6014)

Aktuelle Daten zum malignen Melanom und kutanen Lymphom

J. Utikal, Mannheim (S. 14)

 

  1. Pflugfelder A, Kochs C, Blum A, Capellaro M, Czeschik C, Dettenborn T, Dill D, Dippel E, Eigentler T, Feyer P, Follmann M, Frerich B, Ganten MK, Gärtner J, Gutzmer R, Hassel J, Hauschild A, Hohenberger P, Hübner J, Kaatz M, Kleeberg UR, Kölbl O, Kortmann RD, Krause-Bergmann A, Kurschat P, Leiter U, Link H, Loquai C, Löser C, Mackensen A, Meier F, Mohr P, Möhrle M, Nashan D, Reske S, Rose C, Sander C, Satzger I, Schiller M, Schlemmer HP, Strittmatter G, Sunderkötter C, Swoboda L, Trefzer U, Voltz R, Vordermark D, Weichenthal M, Werner A, Wesselmann S, Weyergraf AJ, Wick W, Garbe C, Schadendorf D; German Dermatological Society; DermatologicCooperative Oncology Group. Malignant melanoma S3-guideline "diagnosis, therapy and follow-up of melanoma". J Dtsch Dermatol Ges. 2013 Suppl 6:1-116, 1-126. 
  2. Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, Garbe C, Jouary T, Hauschild A, Grob JJ, Chiarion-Sileni V, Lebbe C, Mandalà M, Millward M, Arance A, Bondarenko I, Haanen JB, Hansson J, Utikal J, Ferraresi V, Kovalenko N, Mohr P, Probachai V, Schadendorf D, Nathan P, Robert C, Ribas A, DeMarini DJ, Irani JG, Swann S, Legos JJ, Jin F, Mookerjee B, Flaherty K. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet. 2015 May 29. 
  3. Larkin JMG, Yan Y, McArthur GA, Ascierto PA, Liszkay G, Maio M, Mandalà M, Demidov LV, Stroyakovskiy D, Thomas L, De La Cruz-Merino L, Atkinson V, Dutriaux C, Garbe C, Wongchenko M, Rooney IA, Chang I, Hack SP, Dréno B, Ribas A. Update of progression-free survival (PFS) and correlative biomarker analysis from coBRIM: Phase III study of cobimetinib (cobi) plus vemurafenib (vem) in advanced BRAF-mutated melanoma. J Clin Oncol 33, 2015 (suppl; abstr 9006)
  4. Sullivan RJ, Weber JS, Patel SP, Dummer R, Miller WH, Cosgrove D, Carlino MS, Shao-Weng Tan D, Lebbe C, Cipani T, Élez E, Maacke H, Nikolopoulos P, Aout M, De Parseval LA, Ascierto PA. A phase Ib/II study of BRAF inhibitor (BRAFi) encorafenib (ENCO) plus MEK inhibitor (MEKi) binimetinib (BINI) in cutaneous melanoma patients naive to BRAFi treatment. J Clin Oncol 33, 2015 (suppl; abstr 9007)
  5. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbé C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363:711-23.
  6. Daud A, Ribas A, Robert C, Hodi FS, Wolchok JD, Joshua AM, Hwu W, Weber JS, Gangadhar TC, Joseph RW, Dronca RS, Patnaik A, Zarour HM, Kefford R, Lindia JA, Li XN, Ebbinghaus S, Kang SP, Hamid O. Long-term efficacy of pembrolizumab (pembro; MK-3475) in a pooled analysis of 655 patients (pts) with advanced melanoma (MEL) enrolled in KEYNOTE-001. J Clin Oncol 33, 2015 (suppl; abstr 9005)
  7. Hodi FS, Postow MA, Chesney JA, Pavlick AC, Robert C, Grossmann KF, McDermott DF, Linette GP, Meyer N, Giguere JK, Agarwala SS, Shaheen MF, Ernstoff MS, Minor DR, Salama A, Taylor MH, Ott PA, Horak CE, Gagnier P, Wolchok JD. Clinical response, progression-free survival (PFS), and safety in patients (pts) with advanced melanoma (MEL) receiving nivolumab (NIVO) combined with ipilimumab (IPI) vs IPI monotherapy in CheckMate 069 study. J Clin Oncol 33, 2015 (suppl; abstr 9004)
  8. Leiter U, Stadler R, Mauch C, Hohenberger W, Brockmeyer N, Berking C, Sunderkötter C, Kaatz M, Schulte KW, Lehmann P, Vogt T, Ulrich J, Herbst R, Gehring W, Simon JC, Keim U, Garbe C. Survival of SLNB-positive melanoma patients with and without complete lymph node dissection: A multicenter, randomized DECOG trial. J Clin Oncol 33, 2015 (suppl; abstr LBA9002)
  9. Stadler R, Assaf C, Klemke CD, Nashan D, Weichenthal M, Dummer R, Sterry W. Brief S2k guidelines -Cutaneous lymphomas. J Dtsch Dermatol Ges. 2013 Jun;11 Suppl 3:19-28, 20-30
  10. Goldinger SM, Gobbi S, Ding M, Frauchiger AL, Fink-Puches R, Klemke CD, Dréno B, Bagot M, Assaf C, Dummer R. A multicenter, open label, phase II study to assess the efficacy and safety of APO866 in the treatment of patients with refractory or relapsed cutaneous T-cell lymphoma. J Clin Oncol 33, 2015 (suppl; abstr e20044)
  11. Ogura M, Ishida T, Hatake K, Taniwaki M, Ando K, Tobinai K, Fujimoto K, Yamamoto K, Miyamoto T, Uike N, Tanimoto M, Tsukasaki K, Ishizawa K, Suzumiya J, Inagaki H, Tamura K, Akinaga S, Tomonaga M, Ueda R. Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma. J Clin Oncol. 2014 Apr 10;32(11):1157-63.
  12. Mehta-Shah N, Lunning MA, Boruchov AM, Ruan J, Nair S, Lynch P, Byrne R, Moskowitz AJ, Matasar MJ, Gerecitano JF, Hamlin PA, Leonard J, Moskowitz CH, Myskowski PL, Querfeld C, Nolan P, Palomba ML, Straus DJ, Zelenetz AD, Horwitz SM. A phase I/II trial of the combination of romidepsin and lenalidomide in patients with relapsed/refractory lymphoma and myeloma: Activity in T-cell lymphoma. J Clin Oncol 33, 2015 (suppl; abstr 8521)
  13. Purev E, Srinivasan R, Aue G, Stroncek D, Khuu H, Ramos C, Cook L, Cho E, Schmitt M, Childs RW. Outpatient allogeneic hematopoietic cell transplant following alemtuzumab based reduced intensity conditioning in patients with advanced mycosis fungoides/Sezary syndrome. J Clin Oncol 33, 2015 (suppl; abstr 7089)

Immuntherapeutische Ansätze beim kolorektalen Karzinom

A.Block, Hamburg (S. 18)

 

  1. Deng Y, Chi P, Lan P, et al. A multi-center randomized controlled trial of mFOLFOX6 with or without radiation in neoadjuvant treatment of local advanced rectal cancer (FOWARC study): Preliminary results. J Clin Oncol 2015; 33.
  2. Ruers T, Punt CJA, Coevorden Fv, et al. Radiofrequency ablation (RFA) combined with chemotherapy for unresectable colorectal liver metastases (CRC LM): Long-term survival results of a randomized phase II study of the EORTC-NCRI CCSG-ALM Intergroup 40004 (CLOCC). J Clin Oncol 2015; 33:suppl; abstr 350.
  3. Gibbs P, Heinemann V, Sharma NK, et al. SIRFLOX: Randomized phase III trial comparing first-line mFOLFOX6 ± bevacizumab (bev) versus mFOLFOX6 + selective internal radiation therapy (SIRT) ± bev in patients (pts) with metastatic colorectal cancer (mCRC). J Clin Oncol 2015; 33:suppl; abstr 3502.
  4. Bains S, Mahic M, Cvancarova M, et al. Impact of aspirin as secondary prevention in an unselected cohort of 25,644 patients with colorectal cancer: A population-based study. J Clin Oncol 2015;33:suppl; abstr 3504.
  5. Siena S, Sartore-Bianchi A, Lonardi S, et al. Trastuzumab and lapatinib in HER2-amplified metastatic colorectal cancer patients (mCRC): The HERACLES trial. J Clin Oncol 2015; 33:suppl; abstr 3508.
  6. Hong DS, Morris VK, Osta BEE, et al. Phase Ib study of vemurafenib in combination with irinotecan and cetuximab in patients with BRAFmutated metastatic colorectal cancer and advanced cancers. J Clin Oncol 2015;33:suppl; abstr 3511.
  7. Atreya CE, Cutsem EV, Bendell JC, et al. Updated efficacy of the MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E mutated (BRAFm) metastatic colorectal cancer (mCRC). J Clin Oncol 2015;33:suppl; abstr 103.
  8. Giannakis M, Shukla S, Mu JX, et al. Comprehensive molecular characterization of colorectal cancer reveals genomic predictors of immune cell infiltrates. J Clin Oncol 2015;33:suppl; abstr 3505.
  9. Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch repair deficiency. J Clin Oncol 2015;33:suppl; abstr LBA100.

Neue Therapien beim Magen- und Pankreaskarzinom

M. Knödler, Leipzig (S. 22)

 

  1.  ASCO Abstract # 4002: Alderson D et al. Neoadjuvant Chemotherapy for Resectable Oesophageal and Junctional Adenocarcinoma: Results from the UK MRC OE05 trial
  2. ASCO Abstract # 4016: Pauligk C et al. Pathological response to neoadjuvant 5-FU, oxaliplatin and docetaxel (FLOT) versus epirubicin, cisplatin and 5-FU (ECF) in patients with locally advanced, resectable gastric/esophagogastric junction (EGJ) Cancer: Data from the phase II part of the FLOT4 phase III study of the AIO. 
  3. ASCO Abstract # 4000: Cunningham D et al. Phase 3, Randomized, Double-blind, Multicenter, Placebo-controlled Trial of Rilotumumab Plus Epirubicin, Cisplatin, and Capecitabine as First-line Therapy in Patients with Advanced MET-positive Gastric or Gastroesophageal Junction Cancer: RILOMET-1 Study
  4. ASCO Abstract # 4012: Shah MA et al. A phase III study of onartuzumab plus mFOLFOX in patients with metastatic HER2-negative (HER2-) and MET-positive (MET1) adenocarcinoma of the stomach or gastroesophageal junction (GEC).
  5. ASCO Abstract # 4001: Bang YJ et al. Relationship Between PD-L1 Expression and Clinical Outcomes in Patients With Advanced Gastric Cancer Treated With the Anti-PD-1 Monoclonal Antibody Pembrolizumab (MK-3475) in KEYNOTE-012
  6. ASCO Abstract # 4007: Sinn M et al. CONKO-005: Adjuvant therapy in R0 resected pancreatic cancer patients with gemcitabine plus erlotinib versus gemcitabine for 24 weeks-A prospective randomized phase III study.

Aktuelles zum Endometrium- und Ovarialkarzinom

F. Heitz, Essen (S. 30)

 

  1. ASCO Abstract # 5502: Randomized phase II trial of carboplatin-paclitaxel (CP) compared to carboplatin-paclitaxel-bevacizumab (CP-B) in advanced (stage III-IV) or recurrent endometrial cancer: The MITO END-2 trial. Domenica Lorusso, Gabriella Ferrandina, Nicoletta Colombo et al. 
  2. ASCO Abstract # 5500: A randomized phase II study of paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus and ixabepilone/carboplatin/bevacizumab as initial therapy for measurable stage III or IVA, stage IVB or recurrent endometrial cancer, GOG-86P. (#5500) Carol Aghajanian, Virginia L. Filiaci, Don S. Dizon et al. 
  3. ASCO Abstract # 5504: Efficacy and safety of chemotherapy (CT) ± pertuzumab (P) for platinum-resistant ovarian cancer (PROC): AGO-OVAR 2.20/ENGOT-ov14/PENELOPE double-blind placebo-controlled randomized phase III trial.  Christian Kurzeder, Isabel Bover, Frederik Marmé et al.
  4. ASCO Abstract # 5505: Retrospective analysis of candidate predictive tumor biomarkers (BMs) for efficacy in the GOG-0218 trial evaluating front-line carboplatin–paclitaxel (CP) ± bevacizumab (BEV) for epithelial ovarian cancer (EOC). Michael J. Birrer, YounJeong Choi, Mark F. Brady et al.
  5. ASCO Abstract # 5508: Results of ARIEL2: A Phase 2 trial to prospectively identify ovarian cancer patients likely to respond to rucaparib using tumor genetic analysis. Iain A. McNeish, Amit M. Oza, Robert L. Coleman et al.
  6. ASCO Abstract #  5509 und 5510: Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with previously treated, recurrent or refractory ovarian cancer: A phase Ib, open-label expansion trial. Mary L. Disis, Manish R. Patel, Shubham Pant et al.und Antitumor activity and safety of pembrolizumab in patients (pts) with PD-L1 positive advanced ovarian cancer: Interim results from a phase Ib study. Andrea Varga, Sarina Anne Piha-Paul, Patrick Alexander Ott et al. 
  7. ASCO Abstract # 5535: Role of HE4, CA125, and ultrasound in risk assessment in pelvic mass patients: Results from a prospective, multicentric study. E. I. Braicu, U. Torsten, H. Mecke et al.
  8. ASCO Abstract # 5533: The influence of polypharmacy on grade III/IV toxicity, prior discontinuation of chemotherapy and survival in recurrent ovarian cancer patients: An individual participant data meta-analysis of the North-Eastern German Society of Gynecological Oncology (NOGGO) of 1213 patients. Woopen H, Richter R, Chekerov R et al.

Aktuelle Daten zur onkologischen Supportivtherapie

P. Ortner, München (S. 32)

 

  1. Rugo HS et al. Clinical performance of the DigniCap system, a scalp hypothermia system, in preventing chemotherapy-induced alopecia. J Clin Oncol 33, 2015 (suppl; abstr 9518).
  2. Yap YS et al.Predictors of hand-foot syndrome (HFS) in randomised double-blind, placebo-controlled trial of pyridoxine for prevention of capecitabine induced HFS. J Clin Oncol 33, 2015 (suppl; abstr 9596)
  3. Sandler C et al. TOPS: A randomised controlled trial of a multidisciplinary intervention for post-cancer fatigue. J Clin Oncol 33, 2015 (suppl; abstr 9571)
  4. Ciampi de Andrade D et al. A phase III, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of pregabalin in the prevention and reduction of oxaliplatin-induced painful neuropathy (PreOx). J Clin Oncol 33, 2015 (suppl; abstr 3575)
  5. Shinde SS et al. Can pregabalin prevent paclitaxel-associated neuropathy?: A pilot trial. J Clin Oncol 33, 2015 (suppl; abstr 9595).
  6. Schloss JM et al. Pilot trial assessing the efficacy and safety of a supplemental B vitamin complex to reduce the onset and severity of chemotherapy-induced peripheral neuropathy. J Clin Oncol 33, 2015 (suppl; abstr 9604
  7. Nakamura K. et al. Phase II study of preventive effect of topical menthol for chemotherapy-induced peripheral neurotoxicity. J Clin Oncol 33, 2015 (suppl; abstr 9610)
  8. Maroun R. Phase 3 randomized double blind placebo controlled trial evaluating Omega-3 in the prevention of Taxane or Platinum Induced Peripheral Sensory Neuropathy. J Clin Oncol 33, 2015 (suppl; abstr TPS9643)
  9. Rapoport BL, et al. A phase III, randomized, double-blind study of single-dose intravenous fosaprepitant in preventing chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy. J Clin Oncol 33, 2015 (suppl; abstr 9629)
  10. Hesketh PJ et al. Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting (CINV) in moderately emetogenic therapy (MEC). J Clin Oncol 33, 2015 (suppl; abstr 9622)
  11. Jordan K et al. Should all antiemetic guidelines recommend adding a NK1 receptor antagonist (NK1RA) in patients (pts) receiving carboplatin (carbo)? Efficacy evaluation of NEPA, a fixed combination of the NK1RA, netupitant, and palonosetron. J Clin Oncol 33, 2015 (suppl; abstr 9597)
  12. Navari RM et al. Olanzapine versus fosaprepitant for the prevention of nausea and vomiting in patients receiving concurrent chemoradiation treatment. J Clin Oncol 33, 2015 (suppl; abstr 9502).
  13. Abe M et al. Efficacy and safety of olanzapine combined with aprepitant, palonosetron, and dexamethasone for the prevention of cisplatin-based chemotherapy-induced nausea and vomiting for gynecological cancer: KCOG G-1301 phase II trial. J Clin Oncol 33, 2015 (suppl; abstr TPS9639).

Bericht vom 20.Kongress der European Hematology Association in Wien

I. Schmale (S. 36)

 

  1. Dimopoulos MA et al: Carfilzomib and dexamethasone improves progression-free survival and response rates vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: the phase 3 study ENDEAVOR. EHA 2015, Late Breaking Abstract Session, Abstr. #LB2071
  2. Moskowitz CH et al.: Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin´s lymphona at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2015; 385: 1853-62
  3. Walewski JA et al.: Multivariate analysis of PFS from the AETHERA trial: a phase 3 study of brentuximab vedotin consolidation after autologous stem cell transplant for HL. EHA 2015, Oral Abstract Session, Abstr. #S807
  4. Roberts AW et al.: Venetoclax (ABT-199/GDC-0199) combined with Rituximab induces deep responses in patients with relapsed/refractory chronic lymphocytic leukemia. EHA 2015; Oral Abstract Session, Abstr. #S431

Bericht von der 35. Jahrestagung der Deutschen Gesellschaft für Senologie in Leipzig

K. Arnheim (S. 38)

 

  1. Potthoff K et al.; BMC Cancer 2013;13:162-72
  2. Schmidt ME et al.; Contemp Clin Trials 2013;34:117-25
  3. Möbus V et al.; DGS 2015; Abstr. A101
  4. Debald M et al.; DGS 2015; Abstr. A18